Back to Hematology
Hematologyv2017Evidence-Based

Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM)

Predicts survival in patients with myelofibrosis secondary to polycythemia vera (PV) and essential thrombocythemia (ET). This specialized prognostic model was developed specifically for secondary myelofibrosis, incorporating clinical parameters and molecular genetic information to provide superior risk stratification compared to models designed for primary myelofibrosis.

Clinical Input Parameters

years
Range: 18 — 120 years
g/dL
Range: 3 — 20 g/dL
%
Range: 0 — 100 %
×10⁹/L
Range: 1 — 2000 ×10⁹/L
Clinical Assessment
Awaiting Parameters
mysec pm score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

MYSEC-PM Score = (Age × 0.15) + (Hemoglobin <11 g/dL × 2) + (Circulating blasts ≥3% × 2) + (Platelet count <150 × 1) + (Constitutional symptoms × 1) + (CALR unmutated × 2)

Clinical Pearls & Practice Notes

  • MYSEC-PM is specifically designed for patients with myelofibrosis secondary to polycythemia vera (PV) or essential thrombocythemia (ET)
  • This model is superior to IPSS and DIPSS for risk stratification in secondary myelofibrosis patients
  • CALR mutation status is a key molecular parameter - unmutated CALR indicates poor prognosis
  • Age is used as a continuous variable (0.15 points per year) rather than categorical cutoffs
  • The model has been validated in multiple cohorts and is adopted by NCCN and European guidelines
  • Particularly useful for treatment decisions including JAK inhibitor therapy and transplantation timing
  • Should not be used for primary myelofibrosis - use IPSS, DIPSS, or MIPSS70 instead
  • Regular reassessment is recommended as molecular and clinical parameters may evolve over time
  • Constitutional symptoms definition: weight loss >10% in 6 months, night sweats, or fever
  • CALR mutation testing is essential for accurate risk stratification using this model

Evidence & Literature Citations

  1. Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017;31(12):2726-2731. doi: 10.1038/leu.2017.169.
  2. Guglielmelli P, Rotunno G, Pacilli A, Rumi E, Rosti V, Delaini F, et al. Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. Am J Hematol. 2016;91(9):918-22. doi: 10.1002/ajh.24423.
  3. Tefferi A, Guglielmelli P, Lasho TL, Rotunno G, Finke C, Mannarelli C, et al. MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. J Clin Oncol. 2018;36(17):1769-1770. doi: 10.1200/JCO.2018.78.9867.

Score Interpretation Ranges

Low Risk0 – 10.99 pts

Low risk secondary myelofibrosis

Intermediate-1 Risk11 – 13.99 pts

Intermediate-1 risk secondary myelofibrosis

Intermediate-2 Risk14 – 15.99 pts

Intermediate-2 risk secondary myelofibrosis

High Risk16 – 50 pts

High risk secondary myelofibrosis

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.